Jim Cramer on Eli Lilly Stock “Needs Some Kind of Catalyst to Get Things Going”

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently provided insights on. Cramer highlighted it as the most valuable health care company and commented:

“Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion dollars, but it’s really stumbled here. It’s in fourth. I’m going to give it 15:1 odds now. Market cap of $780 billion for the most valuable healthcare company in the world. Lilly’s grown by leaps and bounds over the past few years, thanks to its revolutionary GLP-1 drug… It even got pretty darn close to trillionaire status last year with its market cap peaking at $912 billion in the summer of 2024, where I thought it was going to go over.

Eli Lilly and Company (NYSE:LLY) develops pharmaceuticals for diabetes, obesity, oncology, immunology, neuroscience, and other therapeutic areas.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments